ArticleEClinicalMedicine2023

Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study.

Lucy E M Finnigan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.